Associated Papers
An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations.
Kim KH et al.
Esmo Open, 2025
39874900 (PubMed )
Supplement: mmc1.xlsx › Mutation
Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.
Chavan SS et al.
Blood Cancer Journal, 2017
28234347 (PubMed )
Supplement: bcj201712x1.docx
Select a paper to view details